Enterprise Value
103.4M
Cash
123.4M
Avg Qtr Burn
-8.839M
Short % of Float
0.43%
Insider Ownership
0.00%
Institutional Own.
3.56%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) Details Metastatic breast cancer to brain, Cancer | Phase 2/3 Data readout | |
Eftilagimod Alpha Details Cancer, Soft tissue sarcoma | Phase 2 Data readout | |
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and pembrolizumab Details Non-small cell lung carcinoma, Head and neck cancer, Cancer | Phase 2 Data readout | |
Phase 1 Data readout | ||
IMP761 (Agonist AB) Details COVID-19 | Failed Discontinued |